ClinicalTrials.gg
TerminatedNCT05262517Updated May 16, 2024Results posted

Safety and Efficacy of BHV-3000 (Rimegepant) Orally Disintegrating Tablet for Acute Treatment of Temporomandibular Disorders

A Phase 3 interventional study of Rimegepant and Placebo in Temporomandibular Disorders (TMD), sponsored by Pfizer. Terminated at 32 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-05-16.

Sponsored by Pfizer · Phase 3, Interventional, and Treatment

Why this study was terminated
Strategic decision to discontinue the study based on adjusted clinical development plan. This decision is not based on any safety concerns.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
126
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 59 studies in Temporomandibular Joint Disorders with a site in United States — 17 open to participants now, 20 under way, none of them phase 3. Temporomandibular Joint Disorders · United States.

Enrollment
13th of 46
126 · median 60
Started
2022
with 5 others
Phase 3
2 of 59
none open now
Registered
39th of 59
by date

Among the 59 studies in Temporomandibular Joint Disorders with a site in United States, this one is the 13th largest by enrollment of the 46 interventional ones that give a count, is one of 6 that started in 2022, is one of 2 in phase 3, and was the 39th registered.

Temporomandibular Joint Disorders

593 studies on the registry are indexed under Temporomandibular Joint Disorders; 149 are open to participants now.

Browse Temporomandibular Joint Disorders studies →

Open to participants now

17 of the 59 studies in Temporomandibular Joint Disorders with a site in United States are open now. Recruiting first, the newest first:

12 more — sign in →

All 17 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 75 Temporomandibular Joint Disorders studies recruiting now, 26 (35%) set no upper age limit and 45 (60%) stop at 75 or younger; 7 take children under 18; 23 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 59 studies in Temporomandibular Joint Disorders with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to compare the efficacy and safety of rimegepant versus placebo in the acute treatment of Temporomandibular Disorders (TMD), which are medical conditions involving the temporomandibular joint (the joint connecting the jawbone to the skull) and surrounding muscles and tissues.

03

Conditions studied

  • Temporomandibular Disorders (TMD)

Keywords

  • Temporomandibular Disorders
  • TMD
  • Temporomandibular Joint
  • TMJ
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

* Subject has a minimum 3-month to a maximum 5-year history of temporomandibular disorder diagnosed by a healthcare provider.

  • At least one instance of pain ≥ 6 on a Numeric Rating Scale (NRS) (0-10) in the jaw and/or temple area on either side in the past 30 days prior to the Screening Visit.
  • Subject agrees to study-required restrictions of new pain medication, injection therapy, oral devices, occlusal splint therapy or any other pain management techniques during the course of the study.
  • Subject agrees to study-required methods during the course of the study and female subjects must not be breastfeeding.
  • No abnormality identified on the medical or laboratory evaluation.

Exclusion criteria

Exclusion Criteria:

* Subject has an exclusionary headache, joint, pain, connective tissue, or developmental disorder.

  • Subject has an exclusionary history of trauma, surgery, or radiation treatment to the head and neck.
  • ≥ 33kg/m2.
  • Subject history of exclusionary medical conditions such as disease, cardiovascular conditions, uncontrolled hypertension or diabetes, psychiatric conditions, drug or alcohol abuse, , drug allergies, or any significant and/or unstable medical conditions.
  • Subjects taking/using excluded therapies.
  • Participation in clinical trial with non-biological agents or investigational interventional treatments.
  • Subjects who have previously participated in any BHV-3000/ BMS-927711/ rimegepant study.
  • Planned participation in any other investigational clinical trial while participating in this clinical trial.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
126 participants (actual)

Study arms

  • Experimental
    BHV3000 (rimegepant)

    One dose of rimegepant 75 mg ODT

    Drug: Rimegepant

  • Placebo comparator
    Matching Placebo

    One dose of matching placebo

    Drug: Placebo

Interventions

  • 75 mg ODT

    Also known as: BHV3000

  • DrugPlacebo

    matching placebo

06

What researchers measure

Primary outcomes

  1. Sum of Pain Intensity Difference (SPID) From Baseline to 2-Hours Post-dose (SPID-2)

    The SPID-2 was calculated by multiplying the pain intensity difference (PID) score at each post-dose timepoint by the duration (in hours) since the preceding timepoint, then summing the values over the 2 hours. Participants indicated pain using e-diary at each timepoint (0, 15, 30, 45-, 60-, 90- and 120-minutes post-dose) on an NRS score ranging from 0 (no pain) to 10 (worst imaginable pain). PID: calculated by finding the difference between the NRS score at each timepoint from the baseline NRS score (PID range is -6 \[best\] to 4 \[worst\]). Assuming a baseline pain intensity score of 6, possible score range of SPID-2 was: -12 (best) to 8 (worst). Lower SPID-2 score = more improvement from pain. SPID-2 Best is 2 hours\*-6 = -12 (assuming 0 pain intensity score \[pain-free\] for each timepoint) and 2) Worst is 2 hours\*4 = 8 (assuming 10 pain intensity score \[worst imaginable pain\] for each timepoint).

    Time frame: Baseline (0 hours) to 2-hours post-dose

  2. SPID From Baseline to 24-Hours Post-dose (SPID-24)

    The SPID-24 was calculated by multiplying the PID score at each post-dose timepoint by the duration (in hours) since the preceding timepoint, then summing the values over the 24 hours. Participants indicated pain using e-diary at each timepoint (0, 15, 30, 45, 60, 90 and 120 minutes and 4-, 8-, and 24-hours post-dose) on an NRS score ranging from 0 (no pain) to 10 (worst imaginable pain). PID: calculated by finding the difference between the NRS score at each timepoint from the baseline NRS score (PID range is -6 \[best\] to 4 \[worst\]). Assuming a baseline pain intensity score of 6, possible score range of SPID-24 was: -144 (Best) to 96 (worst). Lower SPID-24 score = more improvement from pain. SPID-24 best and worst scores were calculated as: 1) Best is 24 hours\* -6 = -144 (assuming 0 pain intensity score for each timepoint) and 2) Worst is 24 hours\*4 = 96 (assuming 10 pain intensity score for each timepoint).

    Time frame: Baseline (0 hours) to 24-hours post-dose

Secondary outcomes

  1. Change From Baseline in NRS Score at 2-Hours Post-Dose

    TMD pain was assessed using an NRS score ranging in integers from 0 to 10, with 0 being "no pain" and 10 being "worst imaginable pain."

    Time frame: Baseline (0 hours), 2-hours post-dose

  2. Percentage of Participants Who Experienced Pain Freedom at 2-Hours Post-Dose

    Pain freedom was defined as an NRS score of zero at 2 hours post-dose (yes or no). TMD pain was assessed using an NRS score ranging in integers from 0 to 10, with 0 being "no pain" and 10 being "worst imaginable pain."

    Time frame: Baseline (0 hour) to 2-hours post-dose

  3. Time to Onset of Meaningful Pain Relief

    Time to onset of meaningful pain relief post-dose is defined as the first nominal timepoint at which a 30% reduction of pain from baseline on NRS is achieved. TMD pain was assessed using an NRS score ranging in integers from 0 to 10, with 0 being "no pain" and 10 being "worst imaginable pain." Kaplan-Meier method was used for analysis.

    Time frame: Baseline (0 hours) up to 24 hours post-dose

  4. Time to Onset of Initial Pain Relief

    Time to onset of initial pain relief post-dose is defined as the first nominal timepoint at which a 1-point reduction of pain from baseline on NRS is achieved. TMD pain was assessed using an NRS score ranging in integers from 0 to 10, with 0 being "no pain" and 10 being "worst imaginable pain." Kaplan-Meier method was used for analysis.

    Time frame: Baseline (0 hour) to 24 hours post-dose

  5. Percentage of Participants Using Rescue Medication Within 24 Hours Post-Dose

    Rescue medications included any non-study medication recorded on the rescue medication case report form (CRF) with complete medication dates, and either (1) medication date/time is after the study drug start date/time if the medication time and study drug start time are both not missing, or (2) medication date is on or after study drug start date if the medication time or study drug start time is missing.

    Time frame: Through 24 hours post-dose

07

Results

Posted May 16, 2024

Participant flow

A total of 126 participants were enrolled in the study. Only 87 participants were randomized to treatment and only 71 participants were treated.

Participant flow — Overall Study
MilestoneRimegepant (BHV3000)Placebo
Started4443
Treated3932
Completed3932
Not completed511
Withdrew: Randomized but not treated511

Outcome measures

PrimarySum of Pain Intensity Difference (SPID) From Baseline to 2-Hours Post-dose (SPID-2)

The SPID-2 was calculated by multiplying the pain intensity difference (PID) score at each post-dose timepoint by the duration (in hours) since the preceding timepoint, then summing the values over the 2 hours. Participants indicated pain using e-diary at each timepoint (0, 15, 30, 45-, 60-, 90- and 120-minutes post-dose) on an NRS score ranging from 0 (no pain) to 10 (worst imaginable pain). PID: calculated by finding the difference between the NRS score at each timepoint from the baseline NRS score (PID range is -6 \[best\] to 4 \[worst\]). Assuming a baseline pain intensity score of 6, possible score range of SPID-2 was: -12 (best) to 8 (worst). Lower SPID-2 score = more improvement from pain. SPID-2 Best is 2 hours\*-6 = -12 (assuming 0 pain intensity score \[pain-free\] for each timepoint) and 2) Worst is 2 hours\*4 = 8 (assuming 10 pain intensity score \[worst imaginable pain\] for each timepoint).

Time frame:
Baseline (0 hours) to 2-hours post-dose
Reported as:
Least squares mean · Units on a scale
Sum of Pain Intensity Difference (SPID) From Baseline to 2-Hours Post-dose (SPID-2)
Units on a scaleRimegepant (BHV3000)Placebo
Sum of Pain Intensity Difference (SPID) From Baseline to 2-Hours Post-dose (SPID-2)-3.82 (-5.12 to -2.51)-3.67 (-5.14 to -2.20)
Statistical analysis
  • Rimegepant (BHV3000) vs Placebo · Least square (ls) mean difference: -0.15 · 95% CI -1.78 to 1.48
PrimarySPID From Baseline to 24-Hours Post-dose (SPID-24)

The SPID-24 was calculated by multiplying the PID score at each post-dose timepoint by the duration (in hours) since the preceding timepoint, then summing the values over the 24 hours. Participants indicated pain using e-diary at each timepoint (0, 15, 30, 45, 60, 90 and 120 minutes and 4-, 8-, and 24-hours post-dose) on an NRS score ranging from 0 (no pain) to 10 (worst imaginable pain). PID: calculated by finding the difference between the NRS score at each timepoint from the baseline NRS score (PID range is -6 \[best\] to 4 \[worst\]). Assuming a baseline pain intensity score of 6, possible score range of SPID-24 was: -144 (Best) to 96 (worst). Lower SPID-24 score = more improvement from pain. SPID-24 best and worst scores were calculated as: 1) Best is 24 hours\* -6 = -144 (assuming 0 pain intensity score for each timepoint) and 2) Worst is 24 hours\*4 = 96 (assuming 10 pain intensity score for each timepoint).

Time frame:
Baseline (0 hours) to 24-hours post-dose
Reported as:
Least squares mean · Unit on a scale
SPID From Baseline to 24-Hours Post-dose (SPID-24)
Unit on a scaleRimegepant (BHV3000)Placebo
SPID From Baseline to 24-Hours Post-dose (SPID-24)-104.66 (-125.89 to -83.44)-109.79 (-133.65 to -85.92)
Statistical analysis
  • Rimegepant (BHV3000) vs Placebo · Ls mean difference: 5.12 · 95% CI -21.35 to 31.59
SecondaryChange From Baseline in NRS Score at 2-Hours Post-Dose

TMD pain was assessed using an NRS score ranging in integers from 0 to 10, with 0 being "no pain" and 10 being "worst imaginable pain."

Time frame:
Baseline (0 hours), 2-hours post-dose
Reported as:
Least squares mean · Units on a scale
Change From Baseline in NRS Score at 2-Hours Post-Dose
Units on a scaleRimegepant (BHV3000)Placebo
Change From Baseline in NRS Score at 2-Hours Post-Dose-3.08 (-3.89 to -2.26)-3.28 (-4.19 to -2.38)
Statistical analysis
  • Rimegepant (BHV3000) vs Placebo · Ls mean difference: 0.21 · 95% CI -0.99 to 1.41
SecondaryPercentage of Participants Who Experienced Pain Freedom at 2-Hours Post-Dose

Pain freedom was defined as an NRS score of zero at 2 hours post-dose (yes or no). TMD pain was assessed using an NRS score ranging in integers from 0 to 10, with 0 being "no pain" and 10 being "worst imaginable pain."

Time frame:
Baseline (0 hour) to 2-hours post-dose
Reported as:
Number · Percentage of participants
Percentage of Participants Who Experienced Pain Freedom at 2-Hours Post-Dose
Percentage of participantsRimegepant (BHV3000)Placebo
Percentage of Participants Who Experienced Pain Freedom at 2-Hours Post-Dose10.3 (0.7 to 19.8)15.6 (3.0 to 28.2)
Statistical analysis
  • Rimegepant (BHV3000) vs Placebo · Difference in percentage: -5.2 · 95% CI -21.3 to 10.9
SecondaryTime to Onset of Meaningful Pain Relief

Time to onset of meaningful pain relief post-dose is defined as the first nominal timepoint at which a 30% reduction of pain from baseline on NRS is achieved. TMD pain was assessed using an NRS score ranging in integers from 0 to 10, with 0 being "no pain" and 10 being "worst imaginable pain." Kaplan-Meier method was used for analysis.

Time frame:
Baseline (0 hours) up to 24 hours post-dose
Reported as:
Median · Minutes
Time to Onset of Meaningful Pain Relief
MinutesRimegepant (BHV3000)Placebo
Time to Onset of Meaningful Pain Relief91.3 (56.0 to 233.6)120.3 (62.4 to 233.2)
SecondaryTime to Onset of Initial Pain Relief

Time to onset of initial pain relief post-dose is defined as the first nominal timepoint at which a 1-point reduction of pain from baseline on NRS is achieved. TMD pain was assessed using an NRS score ranging in integers from 0 to 10, with 0 being "no pain" and 10 being "worst imaginable pain." Kaplan-Meier method was used for analysis.

Time frame:
Baseline (0 hour) to 24 hours post-dose
Reported as:
Median · Minutes
Time to Onset of Initial Pain Relief
MinutesRimegepant (BHV3000)Placebo
Time to Onset of Initial Pain Relief45.3 (30.5 to 54.7)45.2 (26.0 to 57.8)
SecondaryPercentage of Participants Using Rescue Medication Within 24 Hours Post-Dose

Rescue medications included any non-study medication recorded on the rescue medication case report form (CRF) with complete medication dates, and either (1) medication date/time is after the study drug start date/time if the medication time and study drug start time are both not missing, or (2) medication date is on or after study drug start date if the medication time or study drug start time is missing.

Time frame:
Through 24 hours post-dose
Reported as:
Number · Percentage of participants
Percentage of Participants Using Rescue Medication Within 24 Hours Post-Dose
Percentage of participantsRimegepant (BHV3000)Placebo
Percentage of Participants Using Rescue Medication Within 24 Hours Post-Dose10.3 (0.7 to 19.8)6.3 (0.0 to 14.6)
Statistical analysis
  • Rimegepant (BHV3000) vs Placebo · Difference in percentage: 4.0 · 95% CI -8.7 to 16.6

Adverse events

Collected over Randomization up to 7 days after study medication administration (maximum up to 52 days, if study medication took on 45th day post randomization, single dose was to be administered on any day from randomization to 45 days post randomization, only when NRS>=6). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Rimegepant (BHV3000)0/39 (0%)0/39 (0%)1/39 (2.6%)
Placebo0/32 (0%)0/32 (0%)3/32 (9.4%)
Most frequent other events
Most frequent other events
EventRimegepant (BHV3000)Placebo
PainGeneral disorders0/391/32
HypertransaminasaemiaHepatobiliary disorders0/391/32
HypoaesthesiaNervous system disorders0/391/32
Bundle branch block rightCardiac disorders1/390/32

Baseline characteristics

Analysis population included participants who were enrolled and received at least 1 dose of study medication. Baseline characteristics tabulated by the treated analysis set.

Age, Continuous
Age, Continuous(Years)Rimegepant (BHV3000)PlaceboTotal
Mean43.1 ± 13.9338.6 ± 12.5341.1 ± 13.42
Sex: Female, Male
Sex: Female, Male(Participants)Rimegepant (BHV3000)PlaceboTotal
Female302555
Male9716
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Rimegepant (BHV3000)PlaceboTotal
Hispanic or Latino282149
Not Hispanic or Latino111122
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Rimegepant (BHV3000)PlaceboTotal
American Indian or Alaska Native000
Asian011
Native Hawaiian or Other Pacific Islander000
Black or African American112
White363066
More than one race101
Unknown or Not Reported101
08

Study locations

32 sites
  • Bruce Nelson, DDS
    Phoenix, Arizona 85020, United States
  • Arizona Research Center
    Phoenix, Arizona 85053, United States
  • The Medici Medical Research, LLC
    Hollywood, Florida 33021, United States
  • The Medici Medical Research
    Hollywood, Florida 33021, United States
  • SouthCoast Research Center, Inc
    Miami, Florida 33136, United States
  • SouthCoast Research Center
    Miami, Florida 33136, United States
  • Oceane7 Medical & Research Center, Inc.
    Miami, Florida 33144, United States
  • Florida Craniofacial Institute
    Tampa, Florida 33607, United States
  • Forcare Clinical Research
    Tampa, Florida 33613, United States
  • Campus Health, Indiana University-Purdue University Indianapolis
    Indianapolis, Indiana 46202, United States
  • IDS-IU Simon Cancer Center (IUSCC)
    Indianapolis, Indiana 46202, United States
  • Indiana University School of Dentistry
    Indianapolis, Indiana 46202, United States
  • University of Kentucky, College of Dentistry
    Lexington, Kentucky 40536, United States
  • TMD, Orofacial Pain and Dental Sleep Medicine Clinic, School of Dentistry, University of Minnesota
    Minneapolis, Minnesota 55455, United States
  • University of Minnesota
    Minneapolis, Minnesota 55455, United States
  • Clinvest Research, LLC
    Springfield, Missouri 65807, United States
  • Clinvest Research
    Springfield, Missouri 65810, United States
  • North Suffolk Neurology
    Commack, New York 11725, United States
  • University of Rochester
    Rochester, New York 14618, United States
  • Duke University
    Raleigh, North Carolina 27617, United States
  • META Medical Research Institute,LLC.
    Dayton, Ohio 45432, United States
  • Meta Medical Research
    Dayton, Ohio 45432, United States
  • Kulkarni Orthodonties
    Springboro, Ohio 45066, United States
  • Perelman Center for Advanced Medicine
    Philadelphia, Pennsylvania 19104, United States
  • University of Pittsburgh
    Pittsburgh, Pennsylvania 15201, United States
  • Red Star Research, LLC
    Lake Jackson, Texas 77566, United States
  • Red Star Research
    Lake Jackson, Texas 77566, United States
  • FMC Science
    Lampasas, Texas 76550, United States
  • JBR Clinical Research
    Salt Lake City, Utah 84107, United States
  • JBR
    Salt Lake City, Utah 84107, United States
  • Northwest Clinical Research Center
    Bellevue, Washington 98007, United States
  • Snoring and Sleep Apnea Center (DC/TMD Exam - Dr. Christian)
    Seattle, Washington 98121, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Data sharing details ↗ · www.pfizer.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2022 to primary completion in May 2023, 12 months.

Results were first posted in May 2024, 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 21, 2022
First posted
Mar 2, 2022
StartActual
May 5, 2022
Primary completionActual
May 18, 2023
CompletionActual
May 18, 2023
Results first posted
May 16, 2024
Last update
May 16, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 16, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05262517
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Mar 2, 2022
Start date
May 5, 2022
Primary completion
May 18, 2023
Completion
May 18, 2023
Results posted
May 16, 2024
Last update
May 16, 2024

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rimegepant

Start the discussion